APPLICATION DOPAMINE AGONISTS IN THE TREATMENT OF RESTLESS LEGS SYNDROME
- Authors: Levin O.S.1, Makhnev S.O.1, Shindryaeva N.N.1, Levin OS1, Makhnev SO1, Shindryayeva NN1
-
Affiliations:
- Issue: No 9 (2011)
- Pages: 17-23
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/278878
- ID: 278878
Cite item
Full Text
Abstract
Keywords
About the authors
Oleg Semenovich Levin
Sergey Olegovich Makhnev
Natal'ya Nikolaevna Shindryaeva
O S Levin
S O Makhnev
N N Shindryayeva
References
- Аверьянов Ю.Н., Подчуфарова Е.В. Синдром беспокойных ног // Неврологический журнал. 1997. № 3. С. 12-16.
- Левин О.С. Синдром беспокойных ног. Экстрапирамидные расстройства. Руководство по диагностике и лечению / Под ред. В.Н. Штока, И.А. Ивановой-Смоленской, О.С. Левина. М., 2002. С. 425-434.
- Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide. Arch Neurol 1982;39:739.
- Akyol A, Kiylioglu N, Kadikoylu G, et al. Iron deficiency anemia and restless legs syndrome: Is there an electrophysiological abnormality? Clin Neurol Neurosurg 2003;106:23-27.
- Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep 1996;19:205-13.
- Allen RP, Picchietti D, Hening WA, et al. Restless legs syndrome: Diagnostic criteria, special considerations, and epidemiology. A report from the Restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med 2003;4:101-19.
- Allen RP. Contraversies and challenges in defining etiology and pathophysiology of restless legs syndrome. Am J Med 2007;120:S.13-21.
- Brindani F, Vitetta F, Gemignani F. Restless legs syndrome: differential diagnosis and management with pramipexole. Clin Interventi Aging 2009;4:305-13.
- Вrodeur C, Montplaisir J, Godbout R, et al. Treatment of restless legs syndrome and periodic movements during sleep with L-DOPA: a double-blind, controlled study. Neurology 1988;38:1845-48.
- Clemens S, Rye D, Hochman S. Restless legs syndrome. Revisiting the dopamine hypothesis from the spinal cord perspective. Neurology 2006;67:125-30.
- Ferini-Strambi L, Aarskog D, Partinen M, et al. Effect of pramipexole on RLS symptoms and sleep: A randomized, double-blind, placebo controlled trial. Sleep Med 2008;9:874-81.
- Garcia-Borreguero D., Allen R.P., Kohnen R. et al. Diagnostic standards for dopaminergic augmentation of restless legs syndrome: report from a World Association of Sleep Medicine - International Restless Legs Syndrome Study Group consensus conference at the Max Planck Institute. Sleep Med 2007;8:520-30.
- Hening WA, Allen RP, Chokroverty S, et al. Restless legs syndrome. Phyladelphia: Saunders 2009:312 P.
- Hogl B, Garcia-Borreguero D, Kohnen R, et al. Progressive development of augmentation during long-term treatment with levodopa in restless legs syndrome: results of a prospective multicenter study. J Neurol 2010;257:230-37.
- Kaplan PW, Allen RP, Buchholz DW, et al. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep 1993;16:717-23.
- Lin SC, Kaplan J, Burger CD, et al. Effect of pramipexole in treatment of resistant restless legs syndrome. Mayo Clin Proc 1998;73:497-500.
- Manconi M, Ferri R, Zucconi M, et al. First night efficacy of pramipexole in restless legs syndrome and periodic legs movements. Sleep Med 2007;8:491-97.
- Montplaisir J, Lapierre O, Warnes H, et al. The treatment of the restless leg syndrome with or without periodic leg movements in sleep. Sleep 1992;15(5):391-95.
- Montplaisir J, Nicolas A, Denesle R, et al. Restless legs syndrome improved by pramipexole. Neurology 1999;52:938-43.
- Montplaisir J, Denesle R, Petit D. Pramipexole in the treatment of restless legs syndrome: a follow-up study. Eur J Neurol 2000;7(Suppl. 1):S.27-31.
- Montplaisir J, Fantini ML, Desautels A, et al. Long-term treatment with pramipexole in restless legs syndrome. Eur J Neurol 2006;13:1306-11.
- Oertel WH, Stiasny-Kolster K, Bergtholdt B, et al. Efficacy of pramipexole in restless legs syndrome: A six-week, multicenter, randomized, double-blind study (effect-RLS study). Mov Disord 2007;22:213-19.
- Oertel WH, Trenkwalder C, Zucconi M, et al. State of the art in restless legs syndrome therapy: practice recommendations for treating restless legs syndrome. Mov Disord 2007;22(Suppl.):S.466-75.
- Partinen M, Hirvonen K, Jama L, et al. Efficacy and safety of Pramipexole in idiopathic restless legs syndrome: A polysomnographic dose finding study - The PRELUDE study. Sleep Med 2006;7:407-17.
- Partinen M, Hirvonen K, Jama L, et al. Open-label study of the long-term efficacy and safety of Pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study). Sleep Med 2008;9:537-41.
- Paulus W, Trenkwalder C. Pathophysiology of dopaminergic therapy - related augmentationin restless legs syndrome. Lancet Neurology 2006;5:878-86.
- Quilici S, Abrams KR, Nicolas A, et al. Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome. Sleep Med 2008;9:715-26.
- Stiasny-Kolster K, Oertel WH. Low-dose pramipexole in the management of restless legs syndrome. Neuropsychobiology 2004;50:65-70.
- Trenkwalder C, Stiasny-Kolster K, Kupsch ., et.al. Controlled withdrawal of pramipexole after 6 months of open label treatment in patients with restless legs syndrome. Mov Disord 2006;21:1404-10.
- Trenkwalder C, Henning WA, Montagna P, et al. Treatment of restless legs syndrome: an evidence-based review and implications for clinical practice. Movement Disorders 2008;23:2267-02.
- Trenkwalder C, Hogl B, Benes H, et al. Augmentation in restless legs syndrome is associated with low ferritin. Sleep Med 2008;9:572-74.
- Winkelman JW, Shahar E, Sharief I, et al. Association of restless legs syndrome and cardiovascular disease in the Sleep Heart Health Study. Neurology 2008;70:35-42.
Supplementary files
![](/img/style/loading.gif)